Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy

Part of paid clinical trials in New York, New York.

Sponsor
The New York Eye & Ear Infirmary
Study ID
NCT01255774
Phase
PHASE3
Status
Unknown

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
51 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    An open-label, study of intravitreally administered ranibizumab

Study Details

The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual acuity in wet AMD, it is important to accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy.

Key Dates

First listed
Dec 7, 2010
Start date
Jun 30, 2007
Status verified
Dec 2011
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab
    Open Label use of Ranibizumab for wet age related macular degeneration

Primary Outcome Measure

Central retinal thickness [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New York Eye and Ear InfirmaryNew YorkNew York10003
Katy W Tai, CCRC
[email protected]
212-979-4251

Find similar trials in New York, NY

By research site
New York Eye and Ear Infirmary· New York, NY

Related Studies